Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Stock analysts at Jefferies Group decreased their Q3 2017 earnings per share estimates for shares of Intellia Therapeutics in a research note issued on Wednesday. Jefferies Group analyst M. Raycroft now forecasts that the company will earn ($0.54) per share for the quarter, down from their prior estimate of ($0.53). Jefferies Group has a “Buy” rating and a $36.00 price target on the stock. Jefferies Group also issued estimates for Intellia Therapeutics’ Q4 2017 earnings at ($0.64) EPS, FY2017 earnings at ($1.99) EPS, FY2018 earnings at ($2.52) EPS, FY2019 earnings at ($2.98) EPS, FY2020 earnings at ($2.62) EPS and FY2021 earnings at ($2.48) EPS.

Several other research analysts have also recently weighed in on the company. Credit Suisse Group set a $24.00 price objective on Intellia Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, May 3rd. Wedbush reiterated an “outperform” rating and set a $25.00 price objective on shares of Intellia Therapeutics in a research report on Wednesday, May 3rd. Zacks Investment Research upgraded Intellia Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, April 18th. Cann reiterated a “market perform” rating on shares of Intellia Therapeutics in a research report on Monday, July 17th. Finally, TheStreet upgraded Intellia Therapeutics from a “d+” rating to a “c-” rating in a research report on Thursday, July 6th. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $25.86.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/08/05/intellia-therapeutics-inc-nasdaqntla-forecasted-to-earn-q3-2017-earnings-of-0-54-per-share.html.

Shares of Intellia Therapeutics (NASDAQ:NTLA) opened at 16.10 on Friday. Intellia Therapeutics has a 1-year low of $10.83 and a 1-year high of $24.90. The firm’s 50-day moving average is $15.83 and its 200-day moving average is $14.14. The firm’s market cap is $581.40 million.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Thursday, August 3rd. The company reported ($0.45) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.42) by $0.03. Intellia Therapeutics had a negative return on equity of 22.70% and a negative net margin of 204.48%. The business had revenue of $5.90 million for the quarter, compared to analyst estimates of $5.83 million. The company’s quarterly revenue was up 40.5% compared to the same quarter last year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. GMT Capital Corp purchased a new position in shares of Intellia Therapeutics during the first quarter worth about $4,657,000. Acadian Asset Management LLC purchased a new position in shares of Intellia Therapeutics during the first quarter worth about $1,355,000. Paulson & CO. Inc. purchased a new position in shares of Intellia Therapeutics during the first quarter worth about $1,107,000. Norges Bank purchased a new position in shares of Intellia Therapeutics during the fourth quarter worth about $886,000. Finally, UBS Group AG raised its position in shares of Intellia Therapeutics by 432.0% in the first quarter. UBS Group AG now owns 60,935 shares of the company’s stock worth $859,000 after buying an additional 49,480 shares during the period. Hedge funds and other institutional investors own 46.99% of the company’s stock.

In other Intellia Therapeutics news, major shareholder Venture Fund Ix L.P. Atlas sold 150,000 shares of the stock in a transaction on Tuesday, July 11th. The stock was sold at an average price of $16.24, for a total transaction of $2,436,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 12.80% of the stock is owned by company insiders.

About Intellia Therapeutics

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

Earnings History and Estimates for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.